Discover
IOVA
Iovance Biotherapeutics, Inc.
10.25
1 x 3.76
1 x 4.98
bid
ask
+
0.23
2.30%
1 @ 07:57 PM
10.23 -0.02 (0.24%)
| Ytd | 275.46% | |
| 1y | 365.91% |
9.83
day range
10.27
1.81
52 week range
10.25
| Open | 10.11 | Prev Close | 10.02 | Low | 9.83 | High | 10.27 | Mkt Cap | 4.64B |
| Vol | 22.88M | Avg Vol | 16.60M | EPS | -0.69 | P/E | N/A | Forward P/E | -37.76 |
| Beta | 0.83 | Short Ratio | 4.57 | Inst. Own | 70.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.67 | 200-d Avg | 4.20 | 1yr Est | 10.22 |
| Income Statement | |||
| Total Revenue | 99.31M | ||
| Revenues (USD) | 99.31M | ||
| Cost of Revenue | 43.60M | ||
| Gross Profit | 55.72M | ||
| Operating Expenses | 107.62M | ||
| Research and Development Expense | 58.85M | ||
| Selling, General and Administrative Expense | 39.27M | ||
| Operating Income | -51.90M | ||
| Income Tax Expense | -1.37M | ||
| Net Income | -47.31M | ||
| Net Income Common Stock | -47.31M | ||
| Net Income Common Stock (USD) | -47.31M | ||
| Consolidated Income | -47.31M | ||
| Earnings per Basic Share | -0.11 | ||
| Earnings per Basic Share (USD) | -0.11 | ||
| Earnings per Diluted Share | -0.11 | ||
| Earning Before Interest & Taxes (EBIT) | -48.69M | ||
| Earning Before Interest & Taxes (USD) | -48.69M | ||
| Weighted Average Shares | 450.19M | ||
| Weighted Average Shares Diluted | 450.19M | ||
| Balance Sheet | |||
| Cash and Equivalents | 116.77M | ||
| Cash and Equivalents (USD) | 116.77M | ||
| Investments | 186.91M | ||
| Investments Current | 186.91M | ||
| Trade and Non-Trade Receivables | 102.12M | ||
| Current Assets | 464.26M | ||
| Property, Plant & Equipment Net | 174.94M | ||
| Total Assets | 915.53M | ||
| Debt Current | 2.67M | ||
| Total Debt | 46.00M | ||
| Current Liabilities | 106.85M | ||
| Debt Non-Current | 43.33M | ||
| Total Liabilities | 179.49M | ||
| Accumulated Retained Earnings (Deficit) | -2.90B | ||
| Accumulated Other Comprehensive Income | 13.08M | ||
| Shareholders Equity | 736.05M | ||
| Shareholders Equity (USD) | 736.05M | ||
| Assets Non-Current | 451.27M | ||
| Total Debt (USD) | 46.00M | ||
| Goodwill and Intangible Assets | 263.89M | ||
| Inventory | 55.59M | ||
| Liabilities Non-Current | 72.64M | ||
| Trade and Non-Trade Payables | 26.21M | ||
| Tax Liabilities | 29.31M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 10.40M | ||
| Net Cash Flow from Financing | 49.29M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -85.73M | ||
| Capital Expenditure | -5.44M | ||
| Issuance (Purchase) of Equity Shares | 50.45M | ||
| Net Cash Flow from Investing | -74.05M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -68.61M | ||
| Net Cash Flow from Operations | -60.84M | ||
| Effect of Exchange Rate Changes on Cash | -124.00K | ||
| Share Based Compensation | 11.73M | ||